What is New Ray Medicine International Holding Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
New Ray Medicine International Holding Enterprise Value Chart
New Ray Medicine International Holding Annual Data
Competitive Comparison of New Ray Medicine International Holding's Enterprise Value
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding's Enterprise Value Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Enterprise Value distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Enterprise Value falls into.
New Ray Medicine International Holding Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding (HKSE:06108) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
New Ray Medicine International Holding's EV-to-EBIT for today is
New Ray Medicine International Holding's current Enterprise Value is HK$-15.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. New Ray Medicine International Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-22.31 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
New Ray Medicine International Holding's EV-to-EBITDA for today is:
New Ray Medicine International Holding's current Enterprise Value is HK$-15.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. New Ray Medicine International Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-22.31 Mil.
New Ray Medicine International Holding's current Enterprise Value is HK$-15.06 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. New Ray Medicine International Holding's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$50.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Enterprise Value Related Terms
Thank you for viewing the detailed overview of New Ray Medicine International Holding's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
New Ray Medicine International Holding (HKSE:06108) Business Description
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06108 has been successfully added to your 